As more cities, like Seattle, are adding psychedelics to their decriminalization list, we’re adding these companies to our top 3 junior psychedelic stocks to add to your portfolio.
Psychedelics are therapeutic drugs known for alleviating mood disorders and depression. Thanks to their fast working therapeutic effects. Examples of psychedelics are psilocybin and LSD (colloquially called “magic mushroom”)
But, their legality turned into a political challenge during the 1960s. This is because the drugs became highly connected to the “hippie lifestyle.” It was frequent in student riots and anti-war demonstrations.
Consequently, the lawmakers of the United States banned most psychedelics, supporting the ban with the Controlled Substances Act, grouping them in the same class as heroin.
Fast-forward half a century, the political force on hippie culture has vanished, making investors, patients, and researchers grow more interest in the medicinal advantages of the drugs. The majority of them would argue that the effectiveness of psychedelics is preferable to the latest antidepressants in relieving mental conditions.
This article will cover the top 3 junior psychedelic stocks and their manufacturers, making significant changes in this sector.
TOP 3 PSYCHEDELIC STOCKS FOR INVESTORS
1. COMP360 – Compass Pathways
Compass Pathways is producing a unique, organic mind lot psilocybin, termed COMP360. This variant treats chronic depression. So far, five reliable studies have been carried out on psilocybin to confirm its health gains. The entire research confirmed that it could relieve depressive symptoms rapidly, with a high level of statistical importance.
Before the year runs out, the company would launch the results of this stage 2 study. This company is leading in the game, developing and research matched up to its competitions. If validated, COMP360 could get between 5 and 11 years of sales exclusivity within the United States and the European Union.
Compass Pathway now possesses a market capital of 1.4 billion dollars. During previous years, the stock decreases up to 10%. However, it did include a vast trading assortment of 30 to 60 dollars for each share.
This is an ideal psychedelic stock for investment. Because it’s ahead in showing that psychedelics have compelling medical advantages, it would be capable of leveraging its intellectual property safety and perfectly handling the multi-billion dollar antidepressant sector with psychedelics. The longevity depends on the success of the clinical trials.
2. MindMed or Mind Medicine
This organization is recognized for making LSD for numerous symptoms – the most upgraded is waiting for stage 2 for curing anxiety. The research compares the capacities of 20 micrograms of LSD in comparison with placebo. Moreover, it would kick off in this year’s Q4 (i.e., 2021).
Mind Medicine established the test with LSD neutralizers available to terminate patients’ hallucinogenic experiences in less than half an hour i.e. if adverse events occur.
Furthermore, MindMed is also affiliating with the UHB (University Hospital of Basel) in producing LSD therapies for symptoms like cluster headaches. Also, they have other psychedelics in various early phase clinical tests. Since its inception, MindMed has raised 204 million dollars from investors. It is supported as well by Bruce Linton i.e., the last co-establisher of Canopy Growth.
Currently, MindMed possesses a market capital of 1.2 billion dollars. The healthcare stocks are about 960% across the past 12 months. Investors can look into MindMed as it now possesses the most flexible pipeline, including psychedelics, as well as a vast exposure to different indications.
3. Cybin
Our third pick for the top 3 junior psychedelic stocks is Cybin.
The flagship drug candidate of Cybin is psilocybin distributed through a sublingual film; it is under evaluation to cure depression. The stage 2 placebo-controlled research would begin sooner or later this year and last for another 1 year.
Cybin is progressing, not only in making psychedelic products. Presently, it is affiliating with neurotechnology firm Kernel to quantify the effects of psychedelics in real-time.
The information is worth so much, as it will give helpful knowledge on how new molecules could aim neurological conditions. Since its establishment, the firm has made over 88,000,000 Canadian dollars. And it came from investors.
Currently, it possesses a market capital of 308,000,000 dollars (U.S). Last November, the stock was about 217% of its inventory. If the momentum is maintained, this can be an ideal period to purchase in.
